The Cancer Precision Medicine Laboratory employs multi-disciplinary approach involving genomics, proteomics and bioinformatics to characterize molecular alterations associated with various cancers. These alterations provide insights into mechanisms underlying molecular pathogenesis of cancers. They can also serve as biomarkers for identification and stratification of patient sub-groups that can benefit from targeted therapeutic intervention strategies. In addition, the lab works on delineating mechanisms of acquired resistance to kinase inhibitors and devising novel strategies to combat therapeutic resistance.
We gratefully acknowledge support from the following organisations and funding bodies: